The standard therapy for women with unexplained infertility is gonadotropin or clomiphene citrate. Ovarian stimulation with letrozole has been proposed to reduce multiple gestations while maintaining live birth rates.
T herapeutic options for couples with unexplained infertility include assisted reproductive technologies, such as in vitro fertilization (IVF) and embryo transfer, and empirical ovarian stimulation combined with intrauterine insemination. The high cost and limited insurance coverage of IVF in all but a few locales in the United States make it an unattainable option for most infertile couples. 1 Empirical ovarian stimulation has been thought to promote childbearing by increasing the number of ova ovulated, as well as possibly by enhancing implantation, placentation, or both through hormonal effects on the endometrium. [2] [3] [4] However, empirical ovarian stimulation (with clomiphene or particularly with gonadotropin) is frequently complicated by the ovarian hyperstimulation syndrome and by multiple gestations, with an increased risk of preterm birth and associated neonatal morbidity and costs. [5] [6] [7] [8] [9] [10] Aromatase inhibitors have been used successfully to induce ovulation in women with the polycystic ovary syndrome. 11 In addition, multiple reports suggest that aromatase inhibitors may be effective alternative agents for ovarian stimulation in couples with unexplained infertility. [12] [13] [14] [15] [16] [17] [18] [19] Their administration is reported to be associated with monofollicular development in most cases, 3, 17 which may result in enhanced fertility and a reduced risk of ovarian hyperstimulation and multiple births, 12, 13, 20 as compared with current standard therapies such as gonadotropin and clomiphene. Use of an aromatase inhibitor to promote conception has not been associated with a significantly increased risk of congenital anomalies. 11, 21 We designed the present randomized trial to assess whether ovarian stimulation with letrozole, an aromatase inhibitor, as compared with clomiphene or gonadotropin, would result in a lower rate of multiple gestation without lowering the likelihood of pregnancy.
Me thods

Study Design
The Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS) clinical trial was conducted by the National Institute of Child Health and Human Development (NICHD) Cooperative Reproductive Medicine Network; the Collaborative Center for Statistics and Science at Yale University served as the data coordinating center. The trial was conducted at 12 clinical sites throughout the United States.
The trial design has been published previously. 22 Briefly, this was a multicenter, randomized clinical trial involving 900 couples with unexplained infertility. Women were between 18 and 40 years of age with regular menses (nine or more cycles per year), had a normal uterine cavity with at least one patent fallopian tube, and had a male partner with a semen specimen of at least 5 million sperm per milliliter. This threshold for the sperm count was used because the protocol incorporated a sperm wash with intrauterine insemination. (World Health Organization [WHO] thresholds for normal sperm counts, which are higher, are based on intercourse rather than insemination.) In addition, a sperm wash was performed to concentrate motile sperm; this approach has been shown to improve pregnancy rates with sperm counts below the WHO threshold. 23 Approval for the study was obtained from the institutional review board at each site. Written informed consent was provided by all female and male participants. The first and last authors assume responsibility for the accuracy and completeness of the data reporting and for the fidelity of the report to the study protocol, which is available with the full text of this article at NEJM.org.
Study Treatment
Women received gonadotropin (Menopur, Ferring Pharmaceuticals), administered by subcutaneous injection, or clomiphene or letrozole, administered orally by means of coated tablets. Gonadotropin was purchased from Ferring; clomiphene and letrozole were acquired and coated by a third-party company; none of these companies had any involvement in the conduct of the trial. Letrozole and clomiphene were assigned in a double-blind fashion; letrozole was administered for ovarian stimulation under Investigational New Drug application 107705 with the Food and Drug Administration. Medications were initiated on day 3, 4, or 5 of the menstrual cycle, with randomization stratified according to study site and age group (18 to 34 years or 35 to 40 years) and performed on the basis of a varying block design, with ovarian stimulation for up to four treatment cycles and intrauterine insemination. Women who conceived were followed through pregnancy and delivery.
The primary outcome was the rate of multiple gestation among women with pregnancies in which fetal heart motion was confirmed on ultrasonography performed at approximately 4 to 6 weeks of gestation; if ultrasonography was performed more than once, we used the highest number of fetal heartbeats identified. The primary outcome was compared first between the letrozole group and the overall standard-therapy group (the clomiphene and gonadotropin groups combined) and then among the three groups, with the use of a superiority design. Secondary outcomes included rates of live birth, multiple gestation with live birth, and pregnancy loss; length of gestation; and maternal, fetal, and neonatal complications. Congenital anomalies were identified at the time of birth or at the time of an examination by a pediatric dysmorphologist, usually within 6 months after birth. Examiners were neither routinely informed nor explicitly kept unaware of the treatment group. We prespecified a 25% reduction in the rate of live births in the letrozole group versus the other two groups combined as the margin in a noninferiority design.
Statistical Analysis
The power calculations and data analysis plan have been published previously. 22 Briefly, we calculated that a sample of 900 couples in this three-group study would provide more than 80% power, at a one-sided alpha level of 0.05 and assuming rates for the primary outcome of 25%, 12.5%, and 6.25% in the gonadotropin, clomiphene, and letrozole groups, respectively. Intention-to-treat analyses were performed primarily to compare the letrozole group with the combined gonadotropin and clomiphene groups (since the latter two groups were receiving current standard ovarian-stimulation agents) and secondarily to compare the letrozole group individually with each of the groups receiving standard treatment. Categorical data are reported as frequencies and percentages; differences in these measures between treatment groups were assessed by means of a chi-square analysis, with Fisher's exact test used for expected frequencies of less than 5. Continuous data are expressed as means ±SD, with a Wilcoxon rank-sum test used for testing differences between two groups, and a Kruskal-Wallis test used for testing differences among the three groups. Analyses were performed with SAS software, version 9.2 (SAS Institute). Statistical significance was defined as a two-sided P value of less than 0.05.
R esult s
Baseline Characteristics
We prescreened 3730 couples. Of the 1220 couples with unexplained infertility who provided written informed consent and completed the screening, 900 were randomly assigned to a treatment group (see Fig. S1 in the Supplementary Appendix, available at NEJM.org), and 746 of those couples completed the study. There were no significant differences in the frequency of dropouts among study groups (gonadotropin group, 17.3%; clomiphene group, 16.3%; and letrozole group, 17.7%) ( Fig. S1 and S2 in the Supplementary Appendix). Baseline characteristics have been reported previously 24 and are presented in Table 1 ; baseline characteristics in the per-protocol analysis are provided in Table S1 in the Supplementary Appendix. Treatment-cycle cancellation rates were 6.9% for gonadotropin, 3.3% for clomiphene, and 3.7% for letrozole (P<0.001 for differences among the three groups) (see Table S2 in the Supplementary Appendix for reasons for cycle cancellation).
Pregnancy Outcomes
Rates of conception, clinical pregnancy (as evidenced by fetal heart activity), and live birth in the letrozole group (Table S3 and Fig. S2 and S3 in the Supplementary Appendix) were within the prespecified noninferiority margin (i.e., were statistically noninferior) but were statistically significantly lower than those in the standardtherapy group (the combined gonadotropin and clomiphene groups) ( Table 2 ). Rates of live birth were 32.2% after gonadotropin administration, 23.3% after clomiphene administration (P = 0.02 for the comparison with gonadotropin), and 18.7% after letrozole administration (P<0.001 for the comparison with gonadotropin) ( Fig. 1A and 1B). The rates of live birth, ongoing clinical pregnancy, and conception per treatment cycle are presented in Table S4 and Fig. S4 in the Supplementary Appendix. There was no significant difference in the time to conception among the three groups (Table S3 in the Supplementary Appendix). Among the women who conceived, there was no significant difference among groups in the incidence of clinical pregnancy ( Table S3 in the Supplementary Appendix). The presence of multiple fetal hearts among women who conceived did not differ significantly between the women who received gonadotropin or clomiphene (combined group) and those who received letrozole (P = 0.15) ( Table S3 in the Supplementary Appendix). Similarly, among women who had a clinical pregnancy, the frequency of ongoing multiple gestation did not differ significantly between the gonadotropin and clomiphene groups combined and the letrozole group (P = 0.14) ( Table 2) . When individual groups were compared, the incidence of multiple clinical pregnancy was significantly higher with gonadotropin than with clomiphene or letrozole ( Table 2 and Fig. 1C ). All the multiple gestations in the clomiphene and letrozole groups were twins; there were 24 twins and 10 triplets in the gonadotropin group (Table S3 in the Sup-plementary Appendix). Two patients with triplet clinical pregnancies underwent selective embryo reduction, resulting in 2 sets of twin live births.
The rate of pregnancy loss among established pregnancies did not differ significantly according to treatment (36.4% with gonadotropin, 29.2% with clomiphene, and 30.6% with letrozole) ( Table S3 in the Supplementary Appendix). Most losses occurred in the first trimester (94.1%, 90.3%, and 96.2% of pregnancy losses, respectively); pregnancies with no identified fetal heart motion accounted for approximately half of the first-trimester losses in each treatment group. There were 21 documented ectopic pregnancies, and 3 losses of pregnancies of unknown location; frequencies of pregnancy loss were similar with the three treatments for loss after identification of fetal heart activity in the first trimester and for loss in the second or third trimester. 24 Plus-minus values are means ±SD. There were no significant differences (P<0.05) among the three groups in any of the baseline characteristics. † The body-mass index is the weight in kilograms divided by the square of the height in meters. ‡ Race or ethnic group was reported by the patients. Some patients chose more than one category, including Hispanic or Latino. 
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T h e ne w e ngl a nd jou r na l o f m e dicine * Clinical pregnancy was defined as an intrauterine pregnancy with fetal heart motion, as determined by transvaginal ultrasonography. Live birth was defined as the delivery of a viable infant. † Ten patients with clinical pregnancy (one in the gonadotropin group, six in the clomiphene group, and three in the letrozole group) were excluded because they were lost to follow-up before delivery. ‡ Multiple gestations were calculated as the number of deliveries with multiple babies divided by the number of women with live births. § P<0.01. ¶ P = 0.001.
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The pregnancy outcomes based on a perprotocol analysis are shown in Table S5 in the Supplementary Appendix. These results were consistent with the results of the intention-to-treat analysis.
Neonatal Outcomes
A total of 272 infants were live-born. There was a significant difference among groups in the mean pregnancy duration overall (P = 0.02) but not for singleton gestations specifically ( Table 3) . As anticipated, the mean gestational age at delivery decreased with an increasing number of fetuses (38.6 weeks for singletons, 35.3 weeks for twins, and 34.2 weeks for triplets [P<0.001]). There were 9 infants (from 8 pregnancies) in whom congenital anomalies were identified (4, 3, and 2 in the gonadotropin, clomiphene, and letrozole groups, respectively) ( Table 3) ; no treatmentspecific patterns were identified ( Table S6 in the Supplementary Appendix). There was 1 neonatal death, which was in the letrozole group and was due to preterm labor and delivery, at approximately 23 weeks of gestation.
Mean birth weights are presented in Table 3 ; for singleton gestations, the mean birth weight did not differ significantly among the three treatment groups. There was also no significant difference among groups in the distribution of the infants according to sex. Among singleton infants, rates of neonatal complications and admission to the neonatal intensive care unit did not differ significantly according to the treatment group. The most common neonatal complications in all groups were jaundice, the respiratory distress syndrome, and intrauterine growth restriction ( Table S7 in the Supplementary Appendix).
Safety
The frequency of individual serious adverse maternal events (before conception or during or after pregnancy) and serious adverse fetal or neonatal events did not differ significantly among the three treatment groups, although cumulative serious adverse events were more common in the gonadotropin group than in the other two groups (P = 0.009) ( Table 4 ). Overall rates of nonserious adverse events were similar among the groups, but the frequencies of specific adverse events differed according to the group. The frequency of abdominal bloating was higher with gonadotropin administration than with the other * Plus-minus values are means ±SD. Differences in outcomes were compared among the three treatment groups. In the clomiphene group, estimated gestational age was missing for one singleton, and birth weight was missing for two singletons; in the gonadotropin and letrozole groups, birth weights were missing for one set of twins. NA denotes not applicable, and NICU neonatal intensive care unit. † P<0.001 for the comparison among the three treatment groups. ‡ P<0.05 for the comparison among the three treatment groups. § P<0.05. ¶ For multiple births, the mean birth weight of each of the twins or triplets was calculated first; this average was used in the calculation of the means ±SD for that treatment group. ‖ Shown are the number of twin or triplet deliveries for which the twins (except one in the letrozole group) or triplets were admitted to the NICU. ** Data shown are only for infants hospitalized for more than 3 days. For twins and triplets, the length of hospitalization was calculated as the average number of days that the twins or triplets were in the hospital. † † One set of twins had congenital malformations; in the other set, only one neonate had a congenital malformation. * The event summary for mothers includes all women with at least one adverse event or serious adverse event. Specific events listed in this table include all the serious adverse events and all the adverse events that were observed in at least 5% of women in any of the treatment groups and that differed significantly among the three groups. † P values are for the comparison among the three treatment groups. The chi-square test or Fisher's exact test was used. ‡ The patient was admitted to the hospital at 34 weeks of gestation for lower abdominal, pelvic, and vaginal pain, with a second admission for management of severe groin pain. § One week after an uncomplicated delivery by cesarean section, the patient presented to the emergency department with shortness of breath. She was admitted to the hospital and evaluated for pulmonary edema. ¶ For details, see Table S6 in the Supplementary Appendix. two treatments. One woman, who was in the gonadotropin group, received a diagnosis of the ovarian hyperstimulation syndrome; also, the frequency of treatment-cycle cancellation owing to concern about possible development of the ovarian hyperstimulation syndrome was higher in the gonadotropin group than in the other two groups (see Table S2 in the Supplementary Appendix) .
A list of maternal serious adverse events (all) and nonserious adverse events (those that occurred in >2% of women in any group) before conception, as well as all other adverse events that occurred after conception, is presented in Table S8 in the Supplementary Appendix. The frequency of placental abnormalities did not differ significantly among the groups ( Table S9 in the Supplementary Appendix).
Discussion
In this study of couples with unexplained infertility, the rate of multiple gestation was not significantly reduced among women treated with letrozole for ovarian stimulation, as compared with a combined group of women receiving current standard therapy (gonadotropin or clomiphene). The multiple-gestation rate in the letrozole group was significantly lower than the rate in the gonadotropin group alone but was similar to the rate in the clomiphene group; as compared with gonadotropin, clomiphene also resulted in a significantly lower rate of multiple gestation. The only higher-order multiple gestations (all triplets) occurred after gonadotropin administration.
Administration of letrozole resulted in rates of conception, clinical pregnancy, and live birth that were statistically noninferior to the rates with clomiphene, according to our prespecified noninferiority margin of 25%. However, clomiphene and letrozole each resulted in significantly lower rates of conception, clinical pregnancy, and live birth, as compared with gonadotropin. In contrast, many reports in the literature have suggested a similar or improved pregnancy rate with an aromatase inhibitor, as compared with standard therapy. [12] [13] [14] [16] [17] [18] 25 Possible explanations for these conflicting results may be the randomized design of our study, our standardized criteria for the timing of gonadotropin administration, the standardized timing of insemination in all treatment groups, or some combination of these factors.
The live birth rate among women receiving clomiphene in this study was slightly higher than the rate observed after clomiphene administration in the Reproductive Medicine Network's Pregnancy in Polycystic Ovarian Syndrome II (PPCOS II) study, 11 which involved women with infertility due to the polycystic ovary syndrome, rather than unexplained infertility. However, in the AMIGOS trial, the rate of live birth was reduced after letrozole administration, whereas in the PPCOS II study, letrozole treatment was associated with a significant increase in live births, as compared with clomiphene treatment. The explanation for this difference is uncertain. It is possible that letrozole has a greater antiestrogenic effect on endometrial development in women with unexplained infertility than in women with the polycystic ovary syndrome, resulting in a suboptimal endometrium or altered hormonal milieu that is detrimental to implantation and placentation. Another possibility is that aromatase inhibition, which led to lower androgen levels in women with unexplained infertility and to higher androgen levels in those with the polycystic ovary syndrome, resulted in differential elevations of tissue androgen levels in the hypothalamus, pituitary, ovary, or endometrium.
In this large study, letrozole was not associated with increased risks of serious adverse maternal, fetal, or neonatal outcomes, as compared with the risks in the gonadotropin and clomiphene groups combined. Longer-term follow-up of these infants is ongoing. Although data about the risk of congenital anomalies after the use of an aromatase inhibitor have been limited, 21 the frequency of congenital anomalies in our trial after treatment with letrozole (3.6%) did not differ significantly from the frequency after treatment with gonadotropin (3.1%) or clomiphene (4.3%).
A limitation of our study is the lack of blinding for the gonadotropin group. In addition, the trial was powered for a comparison of the letrozole group with the gonadotropin and clomiphene groups combined, not for individualized group comparisons. This prespecified primary comparison of letrozole with standard therapy is limited by the fact that the two standard agents had different effects. We did not include a placebo control group because we considered it inappropriate to do so in a study involving infertile couples who had been trying to achieve pregnancy for more than 1 year (mean, almost 3 years). A previous study, which included a control group of women who underwent timed intracervical insemination without ovarian stimulation, showed significantly lower pregnancy and delivery rates in the control group than in the gonadotropin group or the clomiphene group. 9 In conclusion, in our study involving couples with unexplained infertility, the use of letrozole for ovarian stimulation resulted in significantly reduced rates of ongoing clinical pregnancy and live birth, but not of multiple gestations, as compared with a combined group receiving standard therapy (gonadotropin or clomiphene), but the two comparators had different effects on these outcomes. As compared with gonadotropin use, the use of letrozole resulted in lower rates of live birth and multiple gestation, whereas the rates of these outcomes did not differ significantly between letrozole and clomiphene.
